Advance the Development of NK, Gamma-Delta T, Macrophage & NKT Cell Therapies to Develop Cost-Effective Treatments for Liquid and Solid Tumors
The Innate Killer Summit returns for its 7th year as the industry-defining forum advancing the field to achieve clinical success. Spanning the current drug development landscape, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies.
Join over 200 experts to characterize and contrast cell sources, supercharge combinations, optimize CMC workflows, examine expansion protocols for high-quality products at scale, and move the field towards persistent, scalable, and cost-effective innate immune cell therapies.
Promising unpublished data, interactive discussion, and engaging networking opportunities join the 7th Innate Killer Summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.